Generic Emblaveo Availability
Last updated on Apr 10, 2025.
Emblaveo is a brand name of avibactam/aztreonam, approved by the FDA in the following formulation(s):
EMBLAVEO (avibactam sodium; aztreonam - powder;intravenous)
-
Manufacturer: ABBVIE
Approval date: February 7, 2025
Strength(s): EQ 0.5GM BASE/VIAL;1.5GM/VIAL [RLD]
Is there a generic version of Emblaveo available?
No. There is currently no therapeutically equivalent version of Emblaveo available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Emblaveo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Patent 7,112,592
Issued: September 26, 2006
Inventor(s): Lampilas; Maxime et al.
Assignee(s): Aventis Pharma S.A. (N/A, FR)The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: ##STR00001## The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.
Patent expiration dates:
- January 7, 2026✓✓✓
- January 7, 2026
-
Heterocyclic compounds as inhibitors of beta-lactamases
Patent 7,612,087
Issued: November 3, 2009
Inventor(s): Aszodi; Jozsef et al.
Assignee(s): Novexel (Romainville, FR)This invention discloses and claims methods for inhibiting bacterial .beta.-lactamases and treating bacterial infections by inhibiting bacterial .beta.-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a .beta.-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a .beta.-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed. ##STR00001##
Patent expiration dates:
- November 12, 2026✓
- November 12, 2026
-
Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Patent 8,471,025
Issued: June 25, 2013
Inventor(s): Dedhiya; Mahendra G. et al.The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
Patent expiration dates:
- August 12, 2031✓
- August 12, 2031
-
Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Patent 8,835,455
Issued: September 16, 2014
Inventor(s): Dedhiya; Mahendra G. et al.The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
Patent expiration dates:
- October 8, 2030✓
- October 8, 2030
-
Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Patent 8,969,566
Issued: March 3, 2015
Inventor(s): Ronsheim; Melanie Simone et al.The present invention relates to compounds and processes for preparing compounds of Formula (I), ##STR00001## including compounds such as trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (e.g., NXL-104).
Patent expiration dates:
- June 15, 2032✓
- June 15, 2032
-
Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Patent 9,284,314
Issued: March 15, 2016
Inventor(s): Ronsheim Melanie Simone & Racha Saibaba & Lawton Graham Richard & Zhou Shao Hong & Kalyan Yuriy B. & Golden Michael & Milne David & Telford Alexander & Cherryman Janette & Boyd Alistair & Phillips Andrew & Dedhiya Mahendra G.
Assignee(s): Forest Laboratories Holdings Ltd.The present invention relates to compounds and processes for preparing compounds of Formula (I),
Patent expiration dates:
- June 15, 2032✓
- June 15, 2032
-
Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Patent 9,695,122
Issued: July 4, 2017
Inventor(s): Ronsheim Melanie Simone & Racha Saibaba & Lawton Graham Richard & Zhou Shao Hong & Kalyan Yuriy B. & Golden Michael & Milne David & Telford Alexander & Cherryman Janette & Boyd Alistair & Phillips Andrew & Dedhiya Mahendra G.
Assignee(s): Forest Laboratories Holdings Ltd.The present invention relates to compounds and processes for preparing compounds of Formula (I),
Patent expiration dates:
- June 15, 2032✓✓
- June 15, 2032
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- February 7, 2028 - NEW PRODUCT
- February 7, 2033 - GENERATING ANTIBIOTIC INCENTIVES NOW
More about Emblaveo (avibactam / aztreonam)
- Check interactions
- Compare alternatives
- Dosage information
- FDA approval history
- Drug class: monobactams/beta-lactamase inhibitors
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.